Successful treatment of CNS involvement in a patient with widely disseminated PTLD through the addition of intrathecal methotrexate to standard therapy

2021 ◽  
Author(s):  
Katarina M. Semkiu ◽  
Vikas R. Dharnidharka ◽  
Robert J. Hayashi
Keyword(s):  
Successful Treatment ◽  
Standard Therapy ◽  
Intrathecal Methotrexate ◽  
Cns Involvement

Successful treatment of intrathecal methotrexate overdose with folinic acid rescue: a case report

2007 ◽  
Vol 88 (7) ◽  
pp. 780-782 ◽  
Author(s):  
L Riva ◽  
V Conter ◽  
C Rizzari ◽  
M Jankovic ◽  
A Sala ◽  
...  
Keyword(s):  
Case Report ◽  
Folinic Acid ◽  
Successful Treatment ◽  
Intrathecal Methotrexate ◽  
Folinic Acid Rescue

Efficacy and toxicity of dose-adjusted EPOCH-rituximab in adults with newly diagnosed Burkitt lymphoma

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 8035-8035 ◽  
Author(s):  
K. Dunleavy ◽  
B. R. Healey Bird ◽  
S. Pittaluga ◽  
N. Grant ◽  
M. Shovlin ◽  
...  
Keyword(s):  
Burkitt Lymphoma ◽  
Standard Therapy ◽  
Residual Disease ◽  
Tumor Lysis Syndrome ◽  
B Cell Lymphoma ◽  
Aggressive Lymphoma ◽  
Intrathecal Methotrexate ◽  
High Dose ◽  
Highly Effective ◽  
Hiv Negative

8035 Background: Burkitt Lymphoma (BL) is a rare and highly aggressive lymphoma, characterized by a high tumor proliferation rate. While the standard therapy of BL is highly effective, it involves intensive, multi-agent chemotherapy that is associated with considerable treatment-related toxicity and mortality, especially in older patients. We hypothesized that the regimen DA-EPOCH may be effective in BL, based on the observation that it overcomes the adverse effect of high proliferation in diffuse large B-cell lymphoma. Methods: We investigated DA-EPOCH-rituximab (R) in untreated BL in an attempt to maintain the high cure rates of standard therapy with minimal treatment related toxicity. Eligible patients had a diagnosis of untreated BL and could be HIV negative or positive with HIV negative patients (n=13) receiving 6 cycles of DA-EPOCH-R as previously described (Blood 99: 2685, 2002) and HIV positive (n=6) patients receiving 3–6 cycles of DA- EPOCH-R for 1 cycle beyond CR for a minimum of 3 cycles. All patients received intrathecal methotrexate prophylaxis and outpatient therapy where possible. Results: The characteristics of 19 enrolled patients are: median age (range) 29 (18–66) and ECOG PS 1(1–3); stage III/IV 10 (53%); LDH > N 11 (61%); male sex 15 (79%); extranodal sites 13 (68%) and ileocecal disease 13 (68%). No patients so far had CNS involvement at diagnosis. Response is CR/CRu in 100% of patients with one patient receiving consolidative radiotherapy to a site of residual disease. OS and PFS are both 100% and EFS 93.3% at a median potential follow-up time of 29 months. Toxicities were fever/neutropenia in 16%, grade 4 neutropenia in 47% and grade 3/4 thrombocytopenia in 22% of cycles. There was one case of tumor lysis syndrome and no treatment related deaths. Conclusions: DA-EPOCH-R is highly effective in BL. It appears to be associated with much lower toxicity compared to standard high-dose regimens and may significantly advance the therapeutic index of BL treatment. Accrual continues. No significant financial relationships to disclose.

scholarly journals Successful Treatment of Intrathecal Methotrexate Overdose by Using Ventriculolumbar Perfusion and Intrathecal Instillation of Carboxypeptidase G2

1996 ◽  
Vol 71 (2) ◽  
pp. 161-165 ◽  
Author(s):  
Aengus S. O'Marcaigh ◽  
Christopher M. Johnson ◽  
William A. Smithson ◽  
Marc C. Patterson ◽  
Brigitte C. Widemann ◽  
...  
Keyword(s):  
Successful Treatment ◽  
Intrathecal Methotrexate ◽  
Carboxypeptidase G2

scholarly journals Refractory Hypercalcemia in a Jamaican Woman

1970 ◽  
Vol 11 (1) ◽  
Author(s):  
Amaris Balitsky MSc, MD ◽  
Jonathan So, PhD, MD ◽  
Carolyn Chessex, MSc, MD
Keyword(s):  
Vitamin D ◽  
Differential Diagnosis ◽  
Parathyroid Hormone ◽  
T Cell ◽  
Young Woman ◽  
Cell Leukaemia ◽  
Intrathecal Methotrexate ◽  
Bisphosphonate Treatment ◽  
Cns Involvement ◽  
Chop Therapy

The two common differential diagnoses for hypercalcemia are malignancy and hyperparathyroidism. In this case of a young woman with hypercalcemia refractory to bisphosphonate treatment, Vitamin D and parathyroid hormone releasing peptide (PTHrP) levels were normal. She was found to be positive for HTLV-1 and later diagnosed with Adult T-cell leukaemia/ lymphoma, with CNS involvement. After treatment with R-CHOP therapy with intrathecal methotrexate, her symptoms improved and her calcium returned to normal. The differential diagnosis and treatment of hypercalcemia is further discussed.

scholarly journals The success of treatment of chronic hepatitis C in opiate addicts in Clinical center of Vojvodina

2014 ◽  
Vol 67 (3-4) ◽  
pp. 123-130
Author(s):  
Milica Odavic ◽  
Tomislav Preveden
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Successful Treatment ◽  
Standard Therapy ◽  
Drug Users ◽  
Intravenous Drug ◽  
Intravenous Drug Users ◽  
Clinical Center

Introduction: Chronic hepatitis C is a disease with a high prevalence in the population of intravenous drug users. Serious clinical course of the disease, which can lead to cirrhosis of the liver with all its complications, has a large epidemiological and clinical significance. This study was aimed at assessing the success of antiviral treatment of chronic hepatitis C in intravenous drug users and defining indicators of successful treatment in this population. Materials and Methods. This retrospective study included 316 patients treated with standard therapy for chronic hepatitis C, pegylated interferon and ribavirin, at the Department of Infectious Diseases, Clinical Center of Vojvodina in Novi Sad in the period from January 2007 to December 2012. The patients were divided into a group of intravenous drug users (n = 163) and a group of other modes of transmission of hepatitis C virus (n = 153). The indicators of successful treatment were measured in both groups. Results. A total 51.57% of the subjects belonged to the group of intravenous drug users. The therapy was successful in 87.15% of cases, while the success was achieved in only 53.47% of cases in the group of patients infected otherwise. The positive effect of therapy was associated with younger age, shorter duration of infection, low levels of fibrosis and a higher percentage of infected with hepatitis C virus genotypes 2 and 3. Conclusion. The population of intravenous drug users can be effectively treated with the standard therapy for chronic hepatitis C, even more successfully than the population infected in some other way.

Sign in / Sign up

Export Citation Format

Share Document